This article has been reviewed according to Science X's editorial process and policies. Editors have highlighted the following attributes while ensuring the content's credibility:

fact-checked

peer-reviewed publication

trusted source

proofread

Researchers find difference in pancreatic cancer cells, offering new hope for immunotherapy effectiveness

Researchers at Houston Methodist find difference in pancreatic cancer cells, offering new hope for immunotherapy effectiveness
Diagram of the pancreas. Credit: Houston Methodist

A new study has found that pancreatic cancer cells are different based on their location in the pancreas, providing new information about tumors that could lead to better targeted treatments.

Pancreatic (PDAC) is an , and the diagnosis has dramatically increased over the last decade. It is currently the seventh leading cause of cancer deaths in men and women globally and projected to be the third leading cause of cancer-related deaths worldwide by 2030. This increase is due to several factors such as an increase in obesity and diabetes.

Houston Methodist's section chief of gastrointestinal medical oncology, Dr. Maen Abdelrahim, served as first and concept generating author for the article titled, "Comparative molecular profiling of pancreatic ductal adenocarcinoma of the head versus body and tail," published in npj Precision Oncology. The research team discovered that the anatomical location of the pancreatic tumor is a contributing factor for the outcomes of systematic therapy interventions.

Abdelrahim and his established a hypothesis that there is a difference in microenvironments of tumors in the pancreatic head versus the body and tail, particularly the immunotherapy receptors found on each section of the .

"By focusing on biology around the tumor and taking its location on the pancreas into account we can better evaluate our ," said Abdelrahim. "Rather than treating patients under the umbrella of pancreatic malignancy, a shift to a tumor location-based model can seriously alter how clinicians set up preliminary treatment plans."

The team hopes this finding will help clinicians develop a more specific treatment plan and improve patient outcomes.

More information: Maen Abdelrahim et al, Comparative molecular profiling of pancreatic ductal adenocarcinoma of the head versus body and tail, npj Precision Oncology (2024). DOI: 10.1038/s41698-024-00571-4

Journal information: npj Precision Oncology
Provided by Houston Methodist
Citation: Researchers find difference in pancreatic cancer cells, offering new hope for immunotherapy effectiveness (2024, May 1) retrieved 25 June 2024 from https://medicalxpress.com/news/2024-05-difference-pancreatic-cancer-cells-immunotherapy.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.

Explore further

An augmentation to standard treatment of pancreatic ductal adenocarcinoma using five repurposed drugs

75 shares

Feedback to editors